At Jabez, we strongly believe that the future of cancer therapy will be dominated by strategic combinations. Our mission is to develop highly potent, and clinically practical therapeutics that not only demonstrate superior efficacy as standalone treatments but also create powerful synergies when combined with widely used cancer therapies. 

About Jabez

Jabez Biosciences is a clinical-stage biotechnology company that is developing small molecule inhibitors for the treatment of both solid and liquid cancers. Our lead drug candidate, JBZ-001, is a small molecule inhibitor of a crucial enzyme involved in the de novo synthesis of pyrimidine nucleotides, DHODH, that displays highly optimized therapeutic qualities.

Explore Our Science

Our Pipeline

We are actively pursuing clinical investigations in various solid tumor indications and non-Hodgkin lymphoma (NHL), reflecting our commitment to addressing a broad spectrum of oncological needs. Explore our pipeline to see our current and future plans.

Explore Our Pipeline

Meet The Jabez Team

At Jabez Biosciences, we’ve assembled a dream team of industry veterans and world-class scientific minds, all united by a singular mission: to develop best-in-class small molecule therapeutics that revolutionize cancer treatment. 

Tamara Jovonovich, PhD

CEO

20 years in pharmaceutical development; 15 FDA drug approvals

Learn More

Robert Lewis

COO

30 years in pharmaceutical development; 30 FDA drug approvals

Learn More

Brian Cogley

CFO

Over 15 years leading companies in various industries including life sciences and financial services

Learn More

Tamara Jovonovich, PhD

Chief Executive Officer

tjovonovich@jabezbio.com

Tamara Jovonovich brings over two decades of experience in pharmaceutical research, development, and leadership to her role as CEO of Jabez Biosciences. She earned dual Bachelor of Science degrees in Chemistry and Fine Arts from the University of Central Florida in 1996, followed by a Ph.D. in Biophysical Chemistry from the University of Washington in 2000. Tamara further honed her expertise through post-doctoral research at Stanford University and served as a lecturer at San Jose State University before transitioning to the pharmaceutical industry in Palo Alto, CA, in 2004. Since then, she has held key positions at start-up and medium-cap pharmaceutical companies, including Alexza Pharmaceuticals, Cypress Pharmaceuticals, and Pernix Therapeutics, where she contributed to advancing innovative therapies and building successful teams.

Robert Lewis

Chief Operating Officer

rlewis@jabezbio.com

Rob Lewis, co-founder of Jabez Biosciences, has served as the company’s Chief Operating Officer and Director since June 2024. With nearly three decades of experience in the pharmaceutical industry, Rob began his career at TEVA Pharmaceuticals and has held leadership roles at global and mid-tier companies such as Sigma and Cypress Pharmaceuticals. His extensive expertise spans Scientific Affairs, Medical Affairs, Regulatory Affairs, Clinical Affairs, and International and Domestic Business Development. Over his career, Rob has overseen 30 NDA and ANDA FDA drug approvals and successfully led numerous product launches. Since 2012, he has been an entrepreneur, co-founding and taking ownership stakes in multiple biotech, pharmaceutical, and medical device companies, while serving on the board of directors for each. Rob earned his Bachelor’s Degree in Chemistry and Biology from Columbia College.

Brian Cogley

Chief Finance Officer

bcogley@jabezbio.com

Brian is a senior-level financial executive with over 15 years of experience in corporate finance and accounting. He has worked across various industries, including life sciences, pharmaceuticals, financial services, and manufacturing. Brian holds a bachelor’s degree in accounting and an MBA with a concentration in finance from Duquesne University. His expertise in financial management and strategic planning has been instrumental in driving financial performance and operational efficiency in the organizations he has been part of.